📣 VC round data is live. Check it out!

GeneDx Valuation Multiples

Discover GeneDx's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Dian Diagnostics Group, Indegene, Clover Health, Eckert & Ziegler and more.

GeneDx Overview

About GeneDx

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.


Founded

2000

HQ

United States

Employees

1.3K

Website

genedx.com

Financials (LTM)

Revenue: $449M
EBITDA: $25M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

GeneDx Financials

GeneDx reported last 12-month revenue of $449M and EBITDA of $25M.

In the same LTM period, GeneDx generated $314M in gross profit, $25M in EBITDA, and $24M in net income.

Revenue (LTM)


GeneDx P&L

In the most recent fiscal year, GeneDx reported revenue of $428M and EBITDA of $40M.

GeneDx is profitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 9%, and net margin of 10%.

See analyst estimates for GeneDx
LTMLast FY202320242025202620272028
Revenue$449M$428M$203M$305M$428M
Gross Profit$314M$298M$90M$194M$298M
Gross Margin70%70%44%64%70%
EBITDA$25M$40M($136M)($1M)$12M
EBITDA Margin6%9%(67%)(0%)3%
EBIT Margin5%9%(84%)(8%)(3%)
Net Profit$24M$42M($176M)($52M)($21M)
Net Margin5%10%(87%)(17%)(5%)

Financial data powered by Morningstar, Inc.

GeneDx Stock Performance

GeneDx has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


GeneDx's stock price is $53.10.

GeneDx share price increased by 2.1% in the last 30 days, and decreased by 42.1% in the last year.

GeneDx has an EPS (earnings per share) of $1.41.

See more trading valuation data for GeneDx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B2.1%2.1%-17.3%-42.1%$1.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

GeneDx Valuation Multiples

GeneDx trades at 3.5x EV/Revenue multiple, and 62.7x EV/EBITDA.

See NTM and 2027E valuation multiples for GeneDx

EV / Revenue (LTM)


GeneDx Financial Valuation Multiples

As of June 3, 2026, GeneDx has market cap of $2B and EV of $2B.

GeneDx has a P/E ratio of 66.8x.

LTMLast FY202320242025202620272028
EV/Revenue3.5x3.7x7.8x5.2x3.7x
EV/EBITDA62.7x38.9x(11.5x)n/m129.6x
EV/EBIT77.3x39.9x(9.2x)(67.8x)(120.4x)
EV/Gross Profit5.0x5.3x17.5x8.1x5.3x
P/E66.8x37.7x(9.0x)(30.2x)(75.0x)
EV/FCF-110.4x(8.5x)(46.3x)110.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified GeneDx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

GeneDx Margins & Growth Rates

GeneDx grew revenue by 12% but EBITDA decreased by 90% in the last fiscal year.

In the most recent fiscal year, GeneDx reported gross margin of 70%, EBITDA margin of 9%, and net margin of 10%.

See estimated margins and future growth rates for GeneDx

GeneDx Margins

Last FY202420252026202720282029
Gross Margin70%64%70%69%
EBITDA Margin9%(0%)3%1%
EBIT Margin9%(8%)(3%)(1%)
Net Margin10%(17%)(5%)(0%)
FCF Margin3%(11%)3%(5%)

GeneDx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%51%40%12%
Gross Profit Growth10%116%53%10%
EBITDA Growth(90%)(99%)(1064%)(67%)
EBIT Growth(114%)(86%)(44%)(56%)
Net Profit Growth(103%)(70%)(60%)(94%)
FCF Growth(268%)(82%)(142%)(268%)

Data powered by FactSet, Inc. and Morningstar, Inc.

GeneDx Operational KPIs

GeneDx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

GeneDx's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

GeneDx's Rule of X is 31% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for GeneDx
LTMLast FY202320242025202620272028
Rule of 4023%13%---
Bessemer Rule of X49%31%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue22%21%30%22%21%
G&A Expenses to Revenue33%35%66%33%35%
R&D Expenses to Revenue16%17%29%15%17%
Opex to Revenue-73%128%71%73%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

GeneDx Competitors

GeneDx competitors include Dian Diagnostics Group, Indegene, Clover Health, Eckert & Ziegler, JMDC, Personalis, Genus, CareDx, Vazyme Biotech and Azenta.

Most GeneDx public comparables operate across Diagnostics & Genomics, Health Data & Analytics, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Dian Diagnostics Group1.1x1.1x12.8x11.2x
Indegene3.1x3.0x16.6x17.0x
Clover Health0.8x0.7x75.4x44.3x
Eckert & Ziegler3.0x3.0x9.9x10.1x
JMDC5.0x4.0x18.1x15.2x
Personalis13.9x13.2x(13.7x)(10.8x)
Genus2.5x2.5x14.1x12.7x
CareDx2.6x2.4x30.9x24.4x

This data is available for Pro users. Sign up to see all GeneDx competitors and their valuation data.

Start Free Trial

GeneDx VC Funding History

Before going public, GeneDx raised $241M in total equity funding, across 2 rounds.

Last private valuation of GeneDx was $1B, after raising $121M in July 2020 from BlackRock, Blackstone, Connecticut Innovations, and 5 other investors.


GeneDx Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-20Series CBlackRock; Blackstone; Connecticut Innovations; Decheng Capital; Deerfield; Moore Strategic Ventures; Oak HC/FT; S32$121M$1BGeneDx is a genomics company focused on genetic testing and diagnostics, particularly in pediatric and rare disease areas. In July 2020, it completed a Series C funding round led by BlackRock with participation from investors including Blackstone, Connecticut Innovations, Decheng Capital, Deerfield, Moore Strategic Ventures, Oak HC/FT, and S32, raising approximately $121 million as part of its overall $241 million raised across multiple rounds. The round supported GeneDx's expansion in genomic sequencing and interpretation services, leveraging proprietary platforms for clinical diagnostics. Investors like BlackRock and Blackstone provided strategic capital to scale operations amid growing demand for precision medicine. GeneDx had previously raised a Series B of $120 million in August 2019, building momentum toward its later reverse merger in July 2021 and post-IPO activities in 2022. GeneDx's trajectory included acquisitions like Fabric Genomics and public market entry via reverse merger, reflecting ongoing investor interest in its diagnostic capabilities.
Aug-19Series BBlackstone; Connecticut Innovations; Decheng Capital; Oak HC/FT; S32$120M--

Acquisitions by GeneDx

GeneDx has acquired 2 companies to date.

Last acquisition by GeneDx was on April 16th 2025. GeneDx acquired Fabric Genomics for $51M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by GeneDx

Fabric Genomics
GeneDx
Description
Fabric Genomics is a genomic analysis platform delivering clinical decision support for precision medicine in hereditary diseases and oncology. Its end-to-end software processes whole-genome sequencing data with AI algorithms to identify variants and recommend therapies. Oakland-headquartered, Fabric Genomics collaborates with labs like Boston Children's Hospital and national programs in the Middle East. Founded in 2014, the platform analyzes over 100,000 genomes annually, reducing diagnostic turnaround to under 10 days.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
HQ CountryUnited StatesUnited States
HQ City
San Francisco, CA
Washington, DC
Deal Date16 Apr 202518 Jan 2022
Valuation$51M$623M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all GeneDx acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About GeneDx

When was GeneDx founded?GeneDx was founded in 2000.
Where is GeneDx headquartered?GeneDx is headquartered in United States.
How many employees does GeneDx have?As of today, GeneDx has over 1K employees.
Who is the CEO of GeneDx?GeneDx's CEO is Katherine A. Stueland.
Is GeneDx publicly listed?Yes, GeneDx is a public company listed on Nasdaq.
What is the stock symbol of GeneDx?GeneDx trades under WGS ticker.
When did GeneDx go public?GeneDx went public in 2021.
Who are competitors of GeneDx?GeneDx main competitors include Dian Diagnostics Group, Indegene, Clover Health, Eckert & Ziegler, JMDC, Personalis, Genus, CareDx, Vazyme Biotech, Azenta.
What is the current market cap of GeneDx?GeneDx's current market cap is $2B.
What is the current revenue of GeneDx?GeneDx's last 12 months revenue is $449M.
What is the current revenue growth of GeneDx?GeneDx revenue growth (NTM/LTM) is 17%.
What is the current EV/Revenue multiple of GeneDx?Current revenue multiple of GeneDx is 3.5x.
What is the current EBITDA of GeneDx?GeneDx's last 12 months EBITDA is $25M.
What is GeneDx's EBITDA margin?GeneDx's last 12 months EBITDA margin is 6%.
What is the current EV/EBITDA multiple of GeneDx?Current EBITDA multiple of GeneDx is 62.7x.
How many companies GeneDx has acquired to date?As of June 2026, GeneDx has acquired 2 companies.
What was the largest acquisition by GeneDx?$623M acquisition of GeneDx on 18th January 2022 was the largest M&A GeneDx has done to date.
What companies GeneDx acquired?GeneDx acquired GeneDx and Fabric Genomics.
In how many companies GeneDx has invested to date?GeneDx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to GeneDx

Lists including GeneDx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial